Phase 3 Clinical Trials With Primary Completion Dates in March 2017

This is a list of Phase 3 trials with primary completion dates in March 2017 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ARQLArQule, Inc.2017-03-01Phase 3NCT01755767Study of Tivantinib in Subjects With Inoperable Hepatocellular Carcinoma Who Have Been Treated With One Prior Therapy
CLVSClovis Oncology, Inc.2017-03-01Phase 3NCT01968213A Study of Rucaparib as Switch Maintenance Following Platinum-Based Chemotherapy in Patients With Platinum-Sensitive, High-Grade Serous or Endometrioid Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
FGENFibroGen, Inc2017-03-01Phase 3NCT02174627Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis
IONSIonis Pharmaceuticals, Inc.2017-03-01Phase 3NCT01737398Efficacy and Safety of IONIS-TTR Rx in Familial Amyloid Polyneuropathy
LXRXLexicon Pharmaceuticals, Inc.2017-03-01Phase 3NCT02531035A Phase 3 Study to Evaluate the Safety of Sotagliflozin in Patients With Type 1 Diabetes Who Have Inadaquate Glycemic Control With Insulin Therapy Alone
RAREUltragenyx Pharmaceutical Inc.2017-03-01Phase 3NCT02526160Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
SUPNSupernus Pharmaceuticals, Inc.2017-03-01Phase 3NCT02618408Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 1)
TAROTaro Pharmaceutical Industries Ltd.2017-03-01Phase 3NCT02932462Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
TAROTaro Pharmaceutical Industries Ltd.2017-03-01Phase 3NCT02618759Clinical Study to Evaluate the Efficacy and Safety of DSXS in Patients With Mild to Moderate Plaque Psoriasis
TAROTaro Pharmaceutical Industries Ltd.2017-03-01Phase 3NCT02595073Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis